PD-L1 PET/CT to see primary and metastatic PD-L1-related lesions in adults
Official title: Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients
Run by Tianjin Medical University · NCT07618936 · Data updated 2026-11-12
This study tests whether 68Ga/18F-PD-L1 PET/CT can help detect primary and metastatic PD-L1-related tumors in adults.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Tianjin Medical University Academic / other |
| Locations | 3 sites (Hefei, Anhui and 2 other locations) |
| Status | Recruiting |
| Started | June 1, 2026 |
| Main results expected | June 1, 2031 |
| Study ends | June 1, 2031 |
| Registry record updated | September 8, 2026 |
| Trial ID | NCT07618936 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with suspected, newly diagnosed, or previously treated malignant tumors who are scheduled for PD-L1 PET/CT and can provide informed consent.
✕Probably not a fit
Patients with non-malignant lesions or those unable to provide consent may not benefit from this imaging approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational, single-group study evaluates the usefulness of PD-L1-targeted PET/CT imaging to identify malignant lesions in patients with suspected, newly diagnosed, or previously treated PD-L1–related diseases. Subjects undergo 68Ga/18F-PD-L1 PET/CT for initial assessment or recurrence detection, and imaging findings are analyzed using lesion SUVmax to determine sensitivity, specificity, PPV, NPV, and overall accuracy. The study is conducted at multiple sites in China under the lead sponsorship of Tianjin Medical University with collaboration from affiliated hospitals. Eligible participants include adults with suspected or confirmed malignant tumors who are scheduled for PD-L1 PET/CT and able to provide informed consent. Exclusion criteria include non-malignant lesions, pregnancy, and inability to consent.
Why it matters
Potential benefit: If successful, this imaging approach could improve accuracy in identifying PD-L1–related tumors and help guide diagnosis and management.
How similar studies have gone: Prior work using PD-L1–targeted PET tracers has shown promise in some malignancies, but this represents an observational effort in a broader PD-L1–related disease context.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PD-L1 PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: * (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Where it's running
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China Recruiting -
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China Recruiting -
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China Recruiting
Study contacts
- Principal investigator: Haonan Yu, MD — Tianjin Medical University General Hospital
- Study coordinator: Haonan Yu, MD
- Email: dreamadam@126.com
- Phone: +8613821000597
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Real-world first-line atezolizumab for stage IV NSCLC with PD-L1 ≥50% in Türkiye
This project will see how well first-line atezolizumab works and how safe it is for adults with stage IV non-small cell lung cancer whose tumors have PD-L1 ≥50% and no targetable mutations in routine care in Türkiye.
-
FAPI-PET/CT imaging for diagnosing and staging pancreatic cancer
This study will try 18F‑FAPI‑74 PET/CT scans in adults with suspected or recurrent pancreatic cancer to see if they detect lymph node spread and distant metastases more accurately.
-
Establishing a cohort for Alzheimer's disease research in China
This study is trying to understand how brain scans and other health markers relate to Alzheimer's disease in both people with and without cognitive issues in China, to help find ways to detect and prevent the disease early.
-
Using PET/CT imaging to diagnose GLP-1 receptor related diseases
This study is testing a special imaging scan to see if it can help doctors better diagnose cancer in adults who may have diseases related to GLP-1 receptors.
-
Evaluating PSMA PET/CT Imaging for Prostate Cancer Patients
This study is testing a special type of imaging called PSMA PET/CT to see if it can help find cancer in adults who have or might have prostate cancer.
-
Evaluating PET/CT for SSTR-related diseases
This study is testing a new type of PET/CT scan to see if it can help find cancer spots in adults who have tumors related to SSTR diseases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.